
Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) – Stock analysts at HC Wainwright cut their Q1 2027 earnings per share estimates for shares of Alphatec in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst S. Lee now forecasts that the medical technology company will post earnings of $0.03 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Alphatec’s Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.07 EPS and Q4 2027 earnings at $0.15 EPS.
Alphatec (NASDAQ:ATEC – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The company’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 EPS.
Read Our Latest Research Report on ATEC
Alphatec Stock Up 1.7%
ATEC stock opened at $7.06 on Tuesday. The company has a 50-day simple moving average of $9.61 and a 200 day simple moving average of $10.05. Alphatec has a fifty-two week low of $6.70 and a fifty-two week high of $23.29.
Insiders Place Their Bets
In other news, Director David Demski acquired 60,000 shares of the business’s stock in a transaction dated Friday, October 30th. The stock was acquired at an average price of $6.81 per share, for a total transaction of $408,600.00. Following the completion of the acquisition, the director directly owned 491,635 shares in the company, valued at $3,348,034.35. This represents a 13.90% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles acquired 115,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the acquisition, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 13.48% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Alphatec
Several hedge funds and other institutional investors have recently bought and sold shares of ATEC. Integrated Wealth Concepts LLC boosted its position in shares of Alphatec by 83.6% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,035 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 5,026 shares in the last quarter. Allworth Financial LP grew its stake in shares of Alphatec by 26.0% in the 3rd quarter. Allworth Financial LP now owns 8,401 shares of the medical technology company’s stock worth $87,000 after purchasing an additional 1,735 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Alphatec in the 3rd quarter worth approximately $24,355,000. First Trust Advisors LP grew its stake in shares of Alphatec by 22.3% in the 3rd quarter. First Trust Advisors LP now owns 239,325 shares of the medical technology company’s stock worth $2,470,000 after purchasing an additional 43,633 shares during the last quarter. Finally, Private Advisor Group LLC bought a new stake in shares of Alphatec in the 3rd quarter worth approximately $115,000. 66.35% of the stock is currently owned by institutional investors.
Top Alphatec Stories
These are some of the ATEC stories that stood out recently:
- Negative Sentiment: HC Wainwright cut estimates across multiple periods: Q4 2026 EPS fell to $0.02 from $0.07, while full-year forecasts were reduced for 2026 through 2030. For example, its FY2030 estimate declined to $0.74 from $1.19. These revisions may weigh on investor confidence in future profitability.
- Negative Sentiment: ATEC recently traded near its 52-week low, reflecting weak share-price momentum. Alphatec hits new 52-week low
- Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of Alphatec investors, adding potential legal uncertainty. The announcement does not establish that wrongdoing occurred. Pomerantz investor alert
Alphatec Company Profile
Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.
Read More
- Five stocks we like better than Alphatec
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.
